Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Dulaglutide Provides CVD Protection with or without Metformin
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.
Read More »Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Care of the elderly can be very challenging. Can adding yet another medication actually help?
Read More »The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors
Is the risk as substantial as was initially reported?
Read More »Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer
The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss.
Read More »SGLT-2 Inhibitors and the Risk for Urosepsis
Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene?
Read More »The Relationship Between Aerobic Exercise Capacity and Cardiac Dysfunction In T2D
In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.
Read More »Simple Strategies to Prevent Cardiovascular Complications in T2D
Explore three methods to prevent future acute myocardial infarction with diabetes as an underlying agent.
Read More »Heart Rate Variability as a Predictor for the Development of Diabetes
Decreased vagal tone and changes in sympathetic activity may precede the development of cardiometabolic disease or diabetes.
Read More »